Vera Therapeutics, Inc. (NASDAQ:VERA) Receives $81.45 Average Price Target from Brokerages

Vera Therapeutics, Inc. (NASDAQ:VERA) has been assigned a consensus rating of “Moderate Buy” from the twelve ratings firms that are currently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have given a buy rating to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $81.4545.

VERA has been the topic of several research reports. Pivotal Research set a $73.00 price target on shares of Vera Therapeutics in a report on Friday, December 5th. The Goldman Sachs Group increased their price objective on shares of Vera Therapeutics from $55.00 to $95.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. HC Wainwright raised their target price on shares of Vera Therapeutics from $90.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Wolfe Research upgraded shares of Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 target price on the stock in a report on Wednesday, March 11th. Finally, Wedbush upped their price target on shares of Vera Therapeutics from $23.00 to $33.00 and gave the stock a “neutral” rating in a research report on Thursday, December 11th.

Vera Therapeutics Stock Performance

Shares of NASDAQ:VERA opened at $38.86 on Friday. The business has a 50-day moving average of $42.29 and a two-hundred day moving average of $38.04. The firm has a market capitalization of $2.77 billion, a PE ratio of -8.34 and a beta of 1.17. The company has a debt-to-equity ratio of 0.12, a current ratio of 13.64 and a quick ratio of 13.64. Vera Therapeutics has a 12 month low of $18.53 and a 12 month high of $56.05.

Vera Therapeutics (NASDAQ:VERA) last released its quarterly earnings data on Thursday, February 26th. The company reported ($1.39) earnings per share for the quarter, missing the consensus estimate of ($1.34) by ($0.05). During the same quarter last year, the business earned ($0.72) earnings per share. As a group, research analysts forecast that Vera Therapeutics will post -2.89 earnings per share for the current year.

Insider Activity at Vera Therapeutics

In other news, SVP Joseph R. Young sold 3,117 shares of the company’s stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $41.98, for a total value of $130,851.66. Following the completion of the sale, the senior vice president owned 64,722 shares of the company’s stock, valued at $2,717,029.56. This represents a 4.59% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider William D. Turner sold 2,187 shares of the stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $41.98, for a total value of $91,810.26. Following the completion of the sale, the insider owned 45,313 shares of the company’s stock, valued at approximately $1,902,239.74. This trade represents a 4.60% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 33,490 shares of company stock valued at $1,405,910 over the last 90 days. Corporate insiders own 16.30% of the company’s stock.

Hedge Funds Weigh In On Vera Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of VERA. GAMMA Investing LLC grew its position in shares of Vera Therapeutics by 50.5% during the fourth quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock worth $36,000 after buying an additional 236 shares in the last quarter. Los Angeles Capital Management LLC acquired a new stake in Vera Therapeutics in the fourth quarter valued at $46,000. Quantbot Technologies LP acquired a new stake in Vera Therapeutics in the second quarter valued at $51,000. Aster Capital Management DIFC Ltd bought a new position in Vera Therapeutics during the 4th quarter valued at $71,000. Finally, Virtus Investment Advisers LLC boosted its stake in Vera Therapeutics by 14.8% during the 2nd quarter. Virtus Investment Advisers LLC now owns 4,176 shares of the company’s stock valued at $98,000 after acquiring an additional 539 shares during the last quarter. Hedge funds and other institutional investors own 99.21% of the company’s stock.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.